#Spatial Omics Market Size
Explore tagged Tumblr posts
Text
Spatial Omics Market Increasing Adoption of Spatial Omics in Drug Discovery and Diagnostics
Spatial omics refers to technologies that help localize gene expression and other molecular information in cells and tissues at subcellular resolution to analyze biological systems. Spatial omics allows simultaneous mapping of multiple targets in intact biological tissues to understand complex biological processes and disease pathogenesis. The technology helps obtain genomic, transcriptomic and proteomic details from specific cell types or structures within tissues. This provides better insights compared to conventional bulk-omics techniques that generate averaged measurements from biological samples containing mixed cell populations. With its ability to generate molecular spatial information while preserving tissue architecture, spatial omics is finding rising application in drug discovery, diagnostics and clinical research. Global spatial omics market is estimated to be valued at USD 315.5 Mn in 2024 and is expected to exhibit a CAGR of 9.4% during the forecast period (2024-2031).
Growing use of spatial omics techniques like spatial transcriptomics, mass spectrometry imaging and others in academic and pharmaceutical research is a key factor driving market growth. Spatial Omics Market Growth is being widely adopted by pharmaceutical companies for target identification and validation, biomarker discovery, toxicity prediction and drug efficacy evaluation during preclinical development. It is also finding increasing use in clinical applications like cancer diagnostics, immuno-oncology and neuroscience research. Spatial information helps gain a better understanding of tissue heterogeneity, cellular interactions and biomarker correlations, fueling demand for spatial omics technologies. Key Takeaways Key players operating in the spatial omics market are Gilson Company, Inc., Russell Finex Ltd., Retsch GmbH, Lao Soung Machinery Co. Ltd., Endecotts Ltd., Bionics Scientific Technologies Ltd., and Thermo Fischer Scientific, Advantech Manufacturing, Dual Manufacturing Co., Inc., and GKM Siebtechnik GmbH. Key opportunities in the spatial omics market include development of spatial omics assays and kits specific to various disease areas. This will help facilitate broader adoption of the technology across diagnostic and clinical settings. Growing investments by pharmaceutical and biotech companies in spatial biology startups is another opportunity area. Globally, North America currently dominates the spatial omics market owing to significant research funding and presence of major market players. However, Asia Pacific is anticipated to emerge as the fastest growing regional market over the forecast period driven by increasing R&D spending, biotech investments and focus on precision medicine in countries like China, India and Japan. Key players are also expanding their geographical presence across emerging markets through partnerships and new facilities. Market Drivers and Restrain The key driver for the spatial omics market is increasing focus on precision medicine. Spatial omics techniques help gain molecular insights from individual cells and regions within tissues to better understand disease pathogenesis, predict treatment response and develop targeted therapies. This supports the underlying goal of precision medicine to provide personalized healthcare based on individual patient profiles. Another major driver is rising funding for spatial biology research from government and private organizations worldwide as spatial omics holds potential to accelerate drug discovery processes. The high costs of instruments and software tools required for spatial omics experiments act as a key restraint. Spatial profiling techniques currently generate large datasets requiring costly infrastructure for data analysis, storage and sharing. Limited availability of trained professionals with expertise in spatial analysis also poses a challenge. Standardization issues associated with sample preparation, data acquisition and software tools can hamper wider adoption of spatial omics methods. However, technology advancements are expected to progressively address these restraints over the coming years.
Segment Analysis
Spatial omics sub-segment dominates the market currently. Spatial omics techniques help analyze the expression of genes and proteins at a spatial level within a tissue sample. These techniques can capture molecular information from a whole tissue slice or a tissue section in its native spatial context, enabling the visualization and mapping of molecular landscapes with cellular resolution. Advances in spatial omics techniques like multiplexed ion beam imaging (MIBI), multiplexed error-robust fluorescence in situ hybridization (MERFISH), and spatial transcriptomics are driving the growth of this sub-segment. Global Analysis
North America is expected to be the fastest growing as well as the dominating regional market during the forecast period. The presence of leading spatial omics players and availability of research funding for spatial analysis from government as well as private organizations are driving the growth of the market in this region. Asia Pacific is also expected to witness high growth rate owing to increasing research activities in countries like China and India. Research institutions and pharmaceutical companies in Asia Pacific are widely adopting spatial omics techniques for applications like biomarker discovery and drug development.
Gets More Insights on, Spatial Omics Market
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
#Spatial Omics Market Size#Spatial Omics Market Share#Spatial Omics Market Value#Spatial Omics Market Forecast#Spatial Omics#Coherent Market Insights#Spatial Omics Market
0 notes
Text
0 notes
Text
Europe, CIS & Africa Spatial Transcriptomics Market To Reach $256.1 Million By 2030
September 2024 | Report Format: Electronic (PDF) Europe, CIS & Africa Spatial Transcriptomics Market Growth & Trends The Europe, CIS & Africa spatial transcriptomics market size is anticipated to reach USD 256.1 million by 2030, growing at a CAGR of 15.57% from 2024 to 2030, according to a new report by Grand View Research, Inc. The emerging potential of spatial omics analysis for cancer…
View On WordPress
0 notes
Text
0 notes
Text
Spatial OMICS Market Size, Share, Trends, Forecast Report 2030
0 notes
Text
0 notes
Text
An Overview of the Next Generation Sequencers Market: Trends and Insights
The next-generation sequencers (NGS) market is characterized by rapid technological advancements, expanding applications across various fields, and growing adoption of genomic technologies for research, diagnostics, and precision medicine.
Buy Full Report for More Insights into The Next Generation Sequencers Market Forecast
Download a Free Report Sample
Here's an overview of the trends and insights shaping the NGS market:
1. Market Growth and Size:
The NGS market continues to grow rapidly, driven by increasing demand for high-throughput sequencing technologies, declining sequencing costs, and expanding applications in genomics research, clinical diagnostics, and personalized medicine.
Market research reports project robust growth rates for the NGS market, with estimates of the market size reaching billions of dollars globally.
2. Technological Advancements:
Continuous technological advancements in NGS platforms, sequencing chemistry, and bioinformatics tools enhance sequencing accuracy, throughput, and data quality.
Innovations such as single-molecule sequencing, nanopore sequencing, long-read sequencing, and spatial transcriptomics expand the capabilities of NGS technologies and enable new applications in genomic analysis.
3. Expanding Applications:
NGS technologies find applications across a wide range of fields, including genomics, oncology, reproductive health, infectious diseases, agriculture, forensics, and environmental research.
NGS is increasingly used for whole-genome sequencing, exome sequencing, transcriptome analysis, epigenomics, metagenomics, and microbiome studies, driving demand for sequencing services and bioinformatics solutions.
4. Precision Medicine and Clinical Diagnostics:
NGS plays a pivotal role in advancing precision medicine initiatives by enabling comprehensive genomic profiling, molecular diagnostics, and targeted therapies for cancer and rare diseases.
Clinical applications of NGS include cancer genomics, inherited genetic disorders, pharmacogenomics, prenatal screening, infectious disease detection, and liquid biopsy testing, contributing to personalized treatment approaches and improved patient outcomes.
5. Integration with Other Technologies:
Integration of NGS with other technologies, such as artificial intelligence (AI), machine learning, CRISPR/Cas9 gene editing, and single-cell analysis, enhances data analysis, interpretation, and biological insights.
Multi-omics approaches combining genomics, transcriptomics, proteomics, and metabolomics data provide comprehensive insights into complex biological systems and disease mechanisms.
6. Shift towards Clinical Sequencing:
There is a growing trend towards clinical adoption of NGS technologies in healthcare settings, including hospitals, diagnostic laboratories, and academic medical centers.
Regulatory approvals, reimbursement policies, and guidelines for NGS-based tests are facilitating the integration of genomic sequencing into routine clinical practice for disease diagnosis, prognosis, treatment selection, and monitoring.
7. Cost Reduction and Accessibility:
Declining sequencing costs, improvements in sequencing efficiency, and scalability of NGS platforms make genomic sequencing more accessible and affordable for research laboratories and clinical laboratories worldwide.
Increased competition among NGS instrument manufacturers, service providers, and sequencing reagent suppliers drives cost optimization and innovation in the market.
8. Data Management and Bioinformatics:
Effective data management, storage, analysis, and interpretation remain critical challenges in NGS research and clinical applications.
Bioinformatics tools, software solutions, and cloud-based platforms are developed to address the growing volume, complexity, and diversity of genomic data generated by NGS experiments, enabling researchers to extract meaningful insights from large-scale sequencing datasets.
9. Regulatory Landscape and Quality Assurance:
Regulatory agencies worldwide, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), provide guidance and oversight for NGS-based tests, ensuring analytical validity, clinical utility, and quality assurance.
Quality control standards, proficiency testing programs, and accreditation requirements for NGS laboratories promote standardized practices and ensure the reliability and reproducibility of sequencing results.
10. Global Market Dynamics:
The NGS market exhibits regional variations in adoption rates, market penetration, and regulatory frameworks across different geographic regions, influenced by factors such as healthcare infrastructure, funding availability, research priorities, and economic conditions.
Overall, the next-generation sequencers market continues to evolve rapidly, driven by technological innovation, expanding applications, and increasing demand for genomic solutions in research, clinical diagnostics, and healthcare. As NGS technologies mature and become more integrated into routine practice, they hold immense promise for advancing our understanding of the genome and improving patient care in diverse fields of medicine and biology.
0 notes
Text
0 notes
Text
0 notes
Text
Microscope Market Boosted By Rapidly Growing Semiconductor Industry And Healthcare Sector
The global microscope market size is expected to reach USD 20.4 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 7.97% over the forecast period. High demand from the healthcare sector and the rapidly growing semiconductor industry are among the key factors boosting the market growth.
Gain deeper insights on the market and receive your free copy with TOC now @: Microscope Market Report
The establishment of microscopy to promote research activities is also contributing to the product demand. One of the most important applications of microscopes is in surgical interventions. Magnified imaging systems are in high demand for cancer and neuroscience surgical procedures to improve procedural success. Major market players are focusing on developing dedicated microsurgery offerings, such as the spine, cranial, and other multi-disciplinary surgeries.
The growing adoption and rising investments in the development of microscopes by precision manufacturing industries are expected to drive market growth. However, due to the impact of the COVID-19 pandemic companies reported decreases in the revenue in the second quarter of the year 2020, which affected the supply chain of most of the companies. Manufacturers in the market are adopting strategies, such as product innovation by integrating the latest technology and geographic expansion through mergers & acquisitions. For instance, in October 2020, Bruker Corp. launched the Vutara VXL Super-Resolution Fluorescence Microscope, designed for biological imaging at the nanoscale, which can improve the study of nano-level cellular biology, especially in the field of spatial omics imaging.
#Microscope Market Size & Share#Microscope Market Latest Trends#Microscope Market Growth Forecast#COVID-19 Impacts On Microscope Market#Microscope Market Revenue Value#Global Microscope Market
0 notes
Text
Europe, CIS & Africa Spatial Transcriptomics Market To Reach $256.1 Million By 2030
September 2024 | Report Format: Electronic (PDF) Europe, CIS & Africa Spatial Transcriptomics Market Growth & Trends The Europe, CIS & Africa spatial transcriptomics market size is anticipated to reach USD 256.1 million by 2030, growing at a CAGR of 15.57% from 2024 to 2030, according to a new report by Grand View Research, Inc. The emerging potential of spatial omics analysis for cancer…
View On WordPress
0 notes
Text
Spatial OMICS Market Size Worth $ 484.22 Million By 2028: Grand View Research Inc.
Spatial OMICS Market Size Worth $ 484.22 Million By 2028: Grand View Research Inc.
San Francisco, 26 July 2021: The Report Spatial OMICS Market Size, Share & Trends Analysis Report By Technology (Transcriptomics, Genomics, Proteomics), By Product, By Workflow, By Sample Type, By End Use, By Region, And Segment Forecasts, 2021 – 2028 The global spatial OMICS market size is expected to reach USD 484.22 million by 2028, according to a new report by Grand View Research, Inc. It is…
View On WordPress
#Spatial OMICS Industry#Spatial OMICS Market#Spatial OMICS Market 2021#Spatial OMICS Market 2028#Spatial OMICS Market Revenue#Spatial OMICS Market Share#Spatial OMICS Market Size
0 notes
Text
#spatial omics#market forecast#market size#market growth#market research#market demand#astute analytica
0 notes
Text
Omics-Based Clinical Trials Market Size Is Anticipated To Reach $49.5 Billion By 2030
The global omics-based clinical trials market size is anticipated to reach USD 49.5 billion by 2030, according to the new report of Grand View Research, Inc. The market is expected to expand at a CAGR of 7.4% from 2022 to 2030. Omics has turned out to be the most advanced approach in molecular research. It includes all the field of biological sciences that ends with the suffix - omics. Various disciplines can be classified as omics such as proteomics, genomics, transcriptomics, and metabolomics. The outbreak of coronavirus accelerated the adoption of new approaches, models, and technology in clinical trials, this has positively impacted market growth.
The outbreak of COVID-19 has caused havoc and has disrupted almost every sector of industry.
Initially, the outbreak has negatively impacted the ecosystem of clinical trials and affected many ongoing studies for numerous indications. However, in the second half of 2020, researchers started developing innovative therapeutics and vaccines against COVID-19, which has supported the market recovery and growth, and continuance of business by CROs. There has been an increase in the clinical trials activity with oncology trials attaining historically high levels. The extensive research for understanding the COVID-19 infection has turned the attention to the application of omics-based studies.
Browse Full Report: https://www.grandviewresearch.com/industry-analysis/omics-based-clinical-trials-market-report
For instance, in June 2021, a group of researchers at University Hospital Tuebingen initiated a clinical trial on comparative genetic and immune response analysis of different COVID-19 vaccine candidates using a multi-omics approach. The growing application of spatial OMICS, for the identification of biomarkers, is a major factor boosting the growth of the market. To study the efficacy and toxicity of the drug, spatial OMICS play a major role and have simplified drug discovery and development. Biomarker identification along with the clinical application is widely used in drug development and discovery. Biomarkers are used to identify the pathway of the diseases and the progression and help to understand the cause.
The rising prevalence of chronic diseases such as cancer and cardiac disorders and the increasing demand for omics-based clinical trials in developing countries are boosting the market’s growth. Cancer is one of the leading causes of death in the United States. In 2018 alone, there were an estimated 1,735,350 new diagnoses and 609,640 cancer-related deaths. Single-cell multi-OMIC analysis is a novel tool that is opening doors in cancer drug development and further advance the current treatment options. The market is also driven by a rising number of biologics, demand for advanced technologies, and the need for personalized medicines and orphan drugs. Additionally, growing biotechnology and the pharmaceutical industry have propelled the demand for non-invasive instruments, full applications for single-cell multi-omics technology, and conventional labs are bolstering future market growth.
Omics-Based Clinical Trials Market Highlights
By phase type, phase II segment held the largest market share in 2021 with a share of 37.8% due to the major number of phase II omics-based ongoing clinical trials
Based on the study design, interventional studies had the highest market share in 2021 since, among the three types of studies, interventional studies accounted for a larger number of clinical trials, especially in oncology
The oncology segment dominated the indication segment in 2021 owing to the rising research attention in the field and increasing demand for omics-based clinical trials for early detection and prevention of the disease
North America is expected to maintain its lead in the market over the forecast period owing to technological advancements, rising R&D, and the presence of major pharmaceutical and biotechnology players in the region
Key Companies & Market Share Insights
The market for omics-based clinical trials is highly competitive in nature due to the presence of a substantial number of developed as well as medium to small-sized organizations Several market participants are privately held or are a part of private equity firms’ portfolios. For instance, In March 2018, Danaher Corporation acquired Integrated DNA Technologies. This acquisition aimed at expanding Danaher’s presence in the highly attractive genomics market. Another company is Rebus Biosystems Inc., a U.S.-based life science technology company in December 2021, announced that it has acquired the assay assets and IP of EEL Transcriptomics AB, a company that is privately held focused on high-plex spatial transcriptomics based on single-cell resolution. Some of the prominent players in the omics-based clinical trials market include: Parexel International Corporation, Pharmaceutical Product Development (PPD), Charles River Laboratory, ICON plc, SGS SA, Eli Lilly and Company, Pfizer Inc., Covance Inc., Novo Nordisk, Rebus Bio
Request Free Sample Report: https://www.grandviewresearch.com/industry-analysis/omics-based-clinical-trials-market-report
#Omics-Based Clinical Trials Market Size#Omics-Based Clinical Trials Market Share#Omics-Based Clinical Trials Market Trends
0 notes
Text
Spatial Genomics and Transcriptomics Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2030
Spatial Genomics and Transcriptomics Market size was $163.8 million in 2020, and is expected to grow at a value of more than $470.55 million by 2030, registering a CAGR (Compound annual growth rate) of over 11% from 2022 to 2030.
The discovery of spatial reorganisation of the genome in various diseases is expected to increase the use of spatial genome placement patterns in disease diagnosis. Several modest and large-scale retrospective investigations have been conducted to demonstrate the feasibility of using genomic location as a diagnostic tool. This is expected to drive the use of spatial genomics and transcriptomics technologies, resulting in an increase in organic revenue flow in the space. Key players are working to provide technologically enhanced solutions and platforms to better support the research and clinical domain while also increasing their revenue share in various end-use scenarios.
Request a sample copy of Spatial Genomics and Transcriptomics Market
The growth of the spatial genomics and transcriptomics market is fueled by an increase in adoption of these technologies for various applications such as stem cell and cancer research, tissue-specific gene expression studies, embryogenesis and in-vitro fertilisation, and characterization of non-coding RNAs, among others. Furthermore, the rise in the prevalence of genetic illnesses, the use of spatial genomics and transcriptomics in the determination of disease and treatment indicators, as well as a growing preference for tailored treatments, all contribute to the market's growth. During the projection period, however, a scarcity of experienced specialists, as well as ethical and regulatory limits connected with the use of spatial genomics and transcriptome technologies, are projected to stymie market expansion. On the other hand, there has been a spike in spatial genomics innovation.
Global Spatial Genomics and Transcriptomics Market: Segmentations
By Key Players
Akoya Biosciences, Inc.
BioSpyder Technologies Inc.
Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.)
Dovetail Genomics, LLC
Fluidigm Corporation
Genomic Vision SA, Illumina, Inc.
Lunaphore Technologies SA
Nanostring Technologies, Inc.
Natera Inc.
PerkinElmer Inc. (Horizon Discovery Group Plc.)
Rarecyte, Inc.
Rebus Biosystems, LLC
Resolve Biosciences
S2 Genomic
Seven Bridges Genomics
Singular Genomics System, Inc.
Tecan Group Ltd. (Nugen Technologies, Inc.)
Ultivue, Inc.
Veranome Biosystems LLC
Vizgen Corporation
By workflow, the market is fragmented into spatial imaging, spatial analysis, and spatial sequencing. On the basis of product type, the industry is classified into-
• Instruments
o By mode (automated, semi-automated, and manual)
o By type (sequencing platforms, IHC, microscopy, flow cytometry, mass cytometry, and others)
• Consumables
• Software
o Bioinformatics tools
o Imaging tools
o Storage and management databases
Spatial Genomics and Transcriptomics Market: Competitive Landscape
Major market companies are concentrating their efforts on expanding their spatial transcriptomics and genomics impressions by entering key organisations and collaborating with other players. In addition, the companies are making strategic moves to expand their client base around the world. For example, Dovetail Genomics announced the global availability of its Dovetail HiChIP and Micro-C Kits in February 2020, and ReadCoor, Inc. unveiled its first product offering that includes the RC2 equipment and multi-omic spatial sequencing studies. The gadget activates the organization's Fluorescent in Situ Sequencing (FISSEQ) technology.
Dovetail Micro-C units provide a better goal of chromatin interactions at the mononucleosome level, whereas HiChIP technology combines Micro-C and ChIP-seq into a single work process, allowing protein-guided chromatin architectural modifications to be tested.
Purchase Global Spatial Genomics and Transcriptomicss Market Research Report
Table Of Contents (TOC)
1. Global Spatial Genomics and Transcriptomics Market Introduction and Market Overview
2. Global Spatial Genomics and Transcriptomics Market - Executive Summary
3. Spatial Genomics and Transcriptomics Market Trends, Outlook, and Factors Analysis
4. Global Spatial Genomics and Transcriptomics Market: Estimates & Historic Trend Analysis (2018 to 2021)
5. Global Spatial Genomics and Transcriptomics Market Estimates & Forecast Trend Analysis, by Deployment
6. Global Spatial Genomics and Transcriptomics Market Estimates & Forecast Trend Analysis, by Component
7. Global Spatial Genomics and Transcriptomics Market Estimates & Forecast Trend Analysis, by Content Type
8. Global Spatial Genomics and Transcriptomics Market Estimates & Forecast Trend Analysis, by End Use
9. Global Spatial Genomics and Transcriptomics Market Analysis and Forecast, by Region
10. North America Spatial Genomics and Transcriptomics Market: Estimates & Forecast Trend Analysis\
11. Europe Spatial Genomics and Transcriptomics Market: Estimates & Forecast Trend Analysis
12. Asia Pacific Spatial Genomics and Transcriptomics Market: Estimates & Forecast Trend Analysis
13. Middle East & Africa Spatial Genomics and Transcriptomics Market: Estimates & Forecast Trend Analysis
14. Latin America Spatial Genomics and Transcriptomics Market: Estimates & Forecast Trend Analysis
15. Competitive Landscape
16. Company Profiles
17. Assumptions and Research Methodology
18. Conclusions and Recommendations
Key Questions answered in the India Spatial Genomics and Transcriptomics Market Report are:
1. Which product segment grabbed the largest share in the India Spatial Genomics and Transcriptomics market?
2. How is the competitive scenario of the India Spatial Genomics and Transcriptomics market?
3. Which are the key factors aiding the India Spatial Genomics and Transcriptomics market growth?
4. Which region holds the maximum share in the India Spatial Genomics and Transcriptomics market?
5. What will be the CAGR of the India Spatial Genomics and Transcriptomics market during the forecast period?
6. Which application segment emerged as the leading segment in the India Spatial Genomics and Transcriptomics market?
7. Which are the prominent players in the India Spatial Genomics and Transcriptomics market?
8. What key trends are likely to emerge in the India Spatial Genomics and Transcriptomics market in the coming years?
9. What will be the India Spatial Genomics and Transcriptomics market size by 2028?
10. Which company held the largest share in the India Spatial Genomics and Transcriptomics market?
About We Market Research
WE MARKET RESEARCH is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets.
Our strategic market analysis and capability to comprehend deep cultural, conceptual and social aspects of various tangled markets has helped us make a mark for ourselves in the industry. WE MARKET RESEARCH is a frontrunner in helping numerous companies; both regional and international to successfully achieve their business goals based on our in-depth market analysis. Moreover, we are also capable of devising market strategies that ensure guaranteed customer bases for our clients.
Contact Us:
We Market Research
Phone: +1(929)-450-2887
Email: [email protected]
Web:
https://wemarketresearch.com
1 note
·
View note